The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
BackgroundThe Lung Immune Prognostic Index (LIPI) combines the lactate dehydrogenase (LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have shown that LDH and dNLR are associated with the prognosis of advanced non-small cell lung cancer (NSCLC) in patients treated w...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.791496/full |
| _version_ | 1811217511780188160 |
|---|---|
| author | Qianning Zhang Qianning Zhang Xiaoling Gong Xiaoling Gong Lei Sun Lei Sun Liyun Miao Yujie Zhou |
| author_facet | Qianning Zhang Qianning Zhang Xiaoling Gong Xiaoling Gong Lei Sun Lei Sun Liyun Miao Yujie Zhou |
| author_sort | Qianning Zhang |
| collection | DOAJ |
| description | BackgroundThe Lung Immune Prognostic Index (LIPI) combines the lactate dehydrogenase (LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have shown that LDH and dNLR are associated with the prognosis of advanced non-small cell lung cancer (NSCLC) in patients treated with programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. However, previous results were inconsistent, and the conclusions remain unclear. This meta-analysis aimed to investigate the predictive value of pretreatment LDH and dNLR for NSCLC progression in patients treated with PD-1/PD-L1 inhibitors.MethodsPubMed, Embase, and the Cochrane Library were searched by two researchers independently for related literature before March 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were extracted to assess the predictive value of LDH and dNLR. STATA 15. 0 was used to perform the meta-analysis.ResultsA total of 3,429 patients from 26 studies were included in this meta-analysis. The results revealed that high pretreatment LDH was related to poor OS (HR = 1.19, 95%CI = 1.11–1.24, p < 0.001), but not closely related to poor PFS (HR = 1.02, 95%CI = 1.00–1.04, p = 0.023 < 0.05). The pooled results for dNLR suggested that high pretreatment dNLR was related to poor OS (HR = 1.55, 95%CI = 1.33–1.80, p < 0.001) and PFS (HR = 1.33, 95%CI = 1.16–1.54, p < 0.001).ConclusionBoth pretreatment LDH and dNLR have the potential to serve as peripheral blood biomarkers for patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors. However, more studies on LDH are needed to evaluate its predictive value for PFS in patients with NSCLC. |
| first_indexed | 2024-04-12T06:56:03Z |
| format | Article |
| id | doaj.art-780fee3f61f745048609fbc1b0f81eec |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T06:56:03Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-780fee3f61f745048609fbc1b0f81eec2022-12-22T03:43:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.791496791496The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-AnalysisQianning Zhang0Qianning Zhang1Xiaoling Gong2Xiaoling Gong3Lei Sun4Lei Sun5Liyun Miao6Yujie Zhou7Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, ChinaDepartment of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaDepartment of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, ChinaBackgroundThe Lung Immune Prognostic Index (LIPI) combines the lactate dehydrogenase (LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have shown that LDH and dNLR are associated with the prognosis of advanced non-small cell lung cancer (NSCLC) in patients treated with programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. However, previous results were inconsistent, and the conclusions remain unclear. This meta-analysis aimed to investigate the predictive value of pretreatment LDH and dNLR for NSCLC progression in patients treated with PD-1/PD-L1 inhibitors.MethodsPubMed, Embase, and the Cochrane Library were searched by two researchers independently for related literature before March 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were extracted to assess the predictive value of LDH and dNLR. STATA 15. 0 was used to perform the meta-analysis.ResultsA total of 3,429 patients from 26 studies were included in this meta-analysis. The results revealed that high pretreatment LDH was related to poor OS (HR = 1.19, 95%CI = 1.11–1.24, p < 0.001), but not closely related to poor PFS (HR = 1.02, 95%CI = 1.00–1.04, p = 0.023 < 0.05). The pooled results for dNLR suggested that high pretreatment dNLR was related to poor OS (HR = 1.55, 95%CI = 1.33–1.80, p < 0.001) and PFS (HR = 1.33, 95%CI = 1.16–1.54, p < 0.001).ConclusionBoth pretreatment LDH and dNLR have the potential to serve as peripheral blood biomarkers for patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors. However, more studies on LDH are needed to evaluate its predictive value for PFS in patients with NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2022.791496/fulllactate dehydrogenasederived neutrophil-to-lymphocyte ratioimmunotherapynon-small cell lung cancerprognosis |
| spellingShingle | Qianning Zhang Qianning Zhang Xiaoling Gong Xiaoling Gong Lei Sun Lei Sun Liyun Miao Yujie Zhou The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis Frontiers in Oncology lactate dehydrogenase derived neutrophil-to-lymphocyte ratio immunotherapy non-small cell lung cancer prognosis |
| title | The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis |
| title_full | The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis |
| title_fullStr | The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis |
| title_full_unstemmed | The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis |
| title_short | The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis |
| title_sort | predictive value of pretreatment lactate dehydrogenase and derived neutrophil to lymphocyte ratio in advanced non small cell lung cancer patients treated with pd 1 pd l1 inhibitors a meta analysis |
| topic | lactate dehydrogenase derived neutrophil-to-lymphocyte ratio immunotherapy non-small cell lung cancer prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.791496/full |
| work_keys_str_mv | AT qianningzhang thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT qianningzhang thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT xiaolinggong thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT xiaolinggong thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT leisun thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT leisun thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT liyunmiao thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT yujiezhou thepredictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT qianningzhang predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT qianningzhang predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT xiaolinggong predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT xiaolinggong predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT leisun predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT leisun predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT liyunmiao predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis AT yujiezhou predictivevalueofpretreatmentlactatedehydrogenaseandderivedneutrophiltolymphocyteratioinadvancednonsmallcelllungcancerpatientstreatedwithpd1pdl1inhibitorsametaanalysis |